1. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cardiovascular Disease Related Products (1497):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17471A
    Metformin hydrochloride 1115-70-4 99.98%
    Metformin hydrochloride (1,1-Dimethylbiguanide hydrochloride) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin hydrochloride triggers autophagy.
    Metformin hydrochloride
  • HY-13948
    Angiotensin II human 4474-91-3 99.96%
    Angiotensin II human (Angiotensin II) is a vasoconstrictor that mainly acts on the AT1 receptor. Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis.
    Angiotensin II human
  • HY-19363
    GW4869 6823-69-4
    GW4869 is a noncompetitive neutral sphingomyelinase (N-SMase) inhibitor with an IC50 of 1 μM. GW4869 is an inhibitor of exosome biogenesis/release.
    GW4869
  • HY-A0190
    Ceruletide 17650-98-5 99.96%
    Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts.
    Ceruletide
  • HY-B0468
    Isoprenaline hydrochloride 51-30-9 >99.0%
    Isoprenaline hydrochloride is a non-selective beta-adrenergic receptor agonist with potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities.
    Isoprenaline hydrochloride
  • HY-100545
    BAPTA-AM 126150-97-8 99.62%
    BAPTA-AM is a well-known membrane permeable Ca2+ chelator. BAPTA-AM inhibits hERG channels, hKv1.3 and hKv1.5 channels in HEK 293 cells with IC50s of 1.3 μM, 1.45 μM and 1.23 μM, respectively.
    BAPTA-AM
  • HY-101952
    Prostaglandin E2 363-24-6 98.36%
    Prostaglandin E2 is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.
    Prostaglandin E2
  • HY-19424
    Hemin 16009-13-5 >98.0%
    Hemin is an iron-containing porphyrin. Hemin is an Heme oxygenase (HO)-1 inducer.
    Hemin
  • HY-17502
    Simvastatin 79902-63-9 99.81%
    Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
    Simvastatin
  • HY-P0017
    Aprotinin 9087-70-1 >98.0%
    Aprotinin is a bovine pancreatic trypsin inhibitor (BPTI) inhibitor which inhibits trypsin and chymotrypsin with Kis of 0.06 pM and 9 nM, respectively.
    Aprotinin
  • HY-A0064
    Verapamil hydrochloride 152-11-4 99.95%
    Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research.
    Verapamil hydrochloride
  • HY-N0504
    Lovastatin 75330-75-5 99.93%
    Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.
    Lovastatin
  • HY-13441
    (-)-Blebbistatin 856925-71-8 99.42%
    (-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle myosin II.
    (-)-Blebbistatin
  • HY-B0471
    Phenylephrine hydrochloride 61-76-7 99.95%
    (R)-(-)-Phenylephrine hydrochloride is a selective α1-adrenoceptor agonist with pKis of 5.86, 4.87 and 4.70 for α1D, α1B and α1A receptors respectively.
    Phenylephrine hydrochloride
  • HY-15392
    Chroman 1 1273579-40-0 99.90%
    Chroman 1 dihydrochloride is a highly potent ROCK2 inhibitor, with an IC50 of 1 nM. Chroman 1 dihydrochloride also shows inhibitory activities against MRCK, with an IC50 of 150 nM.
    Chroman 1
  • HY-B0879A
    Suramin sodium salt 129-46-4 99.93%
    Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM). Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM). Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.
    Suramin sodium salt
  • HY-N0437
    Progesterone 57-83-0 99.46%
    Progesterone is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy.
    Progesterone
  • HY-D0187
    L-Glutathione reduced 70-18-8 99.83%
    L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.
    L-Glutathione reduced
  • HY-B0285A
    Amiloride hydrochloride 2016-88-8 99.71%
    Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride hydrochloride is a blocker of polycystin-2 (PC2; TRPP2) channel.
    Amiloride hydrochloride
  • HY-10626
    T0901317 293754-55-9 99.91%
    T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα. T0901317 activates FXR with an EC50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.
    T0901317